Evidence map›Paper›PMID 33800837›Full record

ArticleCells2021

Cerebral Insulin Bolus Revokes the Changes in Hepatic Lipid Metabolism Induced by Chronic Central Leptin Infusion.

Vicente Barrios, Elena López-Villar, Laura M Frago, Sandra Canelles, Francisca Díaz-González, Emma Burgos-Ramos, Gema Frühbeck, Julie A Chowen, Jesús Argente

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Vicente BarriosDepartment of Endocrinology, Hospital Infantil Universitario Niño Jesús, Instituto de Investigación La Princesa, E-28009 Madrid, Spain.ORCID 0000-0002-5507-7545
Elena López-VillarDepartment of Endocrinology, Hospital Infantil Universitario Niño Jesús, Instituto de Investigación La Princesa, E-28009 Madrid, Spain.
Laura M FragoDepartment of Endocrinology, Hospital Infantil Universitario Niño Jesús, Instituto de Investigación La Princesa, E-28009 Madrid, Spain.ORCID 0000-0002-5927-9240
Sandra CanellesDepartment of Endocrinology, Hospital Infantil Universitario Niño Jesús, Instituto de Investigación La Princesa, E-28009 Madrid, Spain.
Francisca Díaz-GonzálezInstitute of Medical and Molecular Genetics (INGEMM), IdiPAZ, Hospital Universitario La Paz, Universidad Autónoma de Madrid, E-28049 Madrid, Spain.
Emma Burgos-RamosFaculty of Environmental Sciences and Biochemistry, Universidad de Castilla-La Mancha, E-45071 Toledo, Spain.ORCID 0000-0002-6942-3023
Gema FrühbeckCentro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, E-28029 Madrid, Spain.ORCID 0000-0002-8305-7154
Julie A ChowenDepartment of Endocrinology, Hospital Infantil Universitario Niño Jesús, Instituto de Investigación La Princesa, E-28009 Madrid, Spain.ORCID 0000-0002-4770-2291
Jesús ArgenteDepartment of Endocrinology, Hospital Infantil Universitario Niño Jesús, Instituto de Investigación La Princesa, E-28009 Madrid, Spain.ORCID 0000-0001-5826-0276
Instituto de Salud Carlos III · ESMadrid Institute for Advanced Studies · ESHospital Infantil Universitario Niño Jesús · ESHospital Universitario La Paz · ESUniversity of Castilla-La Mancha · ES

Funding

Ministerio de Ciencia e Innovación FIS PI19/00166Ministerio de Economía, Industria y Competitividad, Gobierno de España BFU 2017-82565-C2-1-R
6 · The paper itself

Abstract

Central actions of leptin and insulin on hepatic lipid metabolism can be opposing and the mechanism underlying this phenomenon remains unclear. Both hormones can modulate the central somatostatinergic system that has an inhibitory effect on growth hormone (GH) expression, which plays an important role in hepatic metabolism. Using a model of chronic central leptin infusion, we evaluated whether an increase in central leptin bioavailability modifies the serum lipid pattern through changes in hepatic lipid metabolism in male rats in response to an increase in central insulin and the possible involvement of the GH axis in these effects. We found a rise in serum GH in leptin plus insulin-treated rats, due to an increase in pituitary GH mRNA levels associated with lower hypothalamic somatostatin and pituitary somatostatin receptor-2 mRNA levels. An augment in hepatic lipolysis and a reduction in serum levels of non-esterified fatty acids (NEFA) and triglycerides were found in leptin-treated rats. These rats experienced a rise in lipogenic-related factors and normalization of serum levels of NEFA and triglycerides after insulin treatment. These results suggest that an increase in insulin in leptin-treated rats can act on the hepatic lipid metabolism through activation of the GH axis.

Indexed as

AnimalsFatty Acids, NonesterifiedGene Expression RegulationGrowth HormoneHypothalamusInjections, IntravenousInjections, IntraventricularInsulinLeptinLipid MetabolismLiverMalePituitary GlandRatsRats, WistarReceptors, SomatostatinFatty Acids, NonesterifiedGrowth HormoneInsulinLeptinReceptors, SomatostatinRNA, MessengerSstr2 protein, ratTriglyceridesgrowth hormone axisinsulin signalingleptinlipid metabolismliver

Identifiers

PMID33800837
PMCPMC8000796
OpenAlexW3135426275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.